Member Info for KonarA

that's just it - I don't think it was ever "halted" "suspended" or "stopped" however you want to word it. I think recruitment continued throughout, we were just unable to get suitable candidates.

@Chester18 - quite a few times i have seen you write that the "trial was halted". I think maybe you need to be clearer on this. A formal trial "halting" would mean that recruitment has been suspended, usually done where there has been a serious incident that needs investigating. I am not aware (correct me if i am wrong) but the trial was never "halted". Recruitment became practically impossible, due to so many people failing the inclusion criteria, but I don't believe it was ever stopped.

@kashdog - the trial completion date IS NOT the same as any potential data release. The trial complete date is when all data for all patients (including any folllow up investigations) has been compiled, analysed and reported on. Scancell have already said many times that they will release interim data from all of their trials. But then I have made this point to you before... at least a few times I believe.

Burble - thank you for your response. I believe the case i read about was in the "propped up" category, where the sudden removal of the tumour had fatal consequences. Maybe it is something the clinicians have learnt to be more aware of when trying these novel treatments for solid tumors. Hopefully the Modi-1 trial will destroy those tumors in a controlled way!

@Burble

I seem to remember in the early days of Checkpoint Inhibitors, that there were complications resulting from the speed with which tumours were destroyed. If i remember correctly it was to do with such things as the cavity left behind.

Given that moditope in theory works best the more the tumour cells are stressed (making it ideal for late stage bulky tumours) is it possible that Moditope could encounter problems in this area? In some ways it would be a nice problem to have, having to deal with the consequences of nuking tumors, but could this also be a risk to the trial? (i.e. having to pause whilst a death is investigated for example)

And finally, are there any other physiological consequences of the rapid destruction of a tumor? Forgive my layman's terms here, but whilst cell breakdown and turn over is part of the normal function of the body, could such a rapid breakdown lead to some form of toxicity?

Thanks in advance.

and this picture may remain true right up until the day that hasiba sells and Scancell drop a Multi -billion £ deal in an RNS. At which point GF sails off into the distance on their yacht.

Everyone's investment strategy is entirely their own to make, and not subject to judgement by others. Personally i don't have the time to trade backwards and forwards, so i invest in long term promise and hope it delivers.

But all of that is irrelevant to the point I was making, which is the company fail to publicise most of their progress/success. Scancell may well have been a better "year on year winner" if the BoD made more of an effort to support the SP.

with Scancell, the hype often fills the vacuum of missing company announced news. Time and time again Scancell fail to promote their own progress or good news, leaving others to do it for them. I've long since been of the opinion that the BoD are quite content keeping a stable shareholder base at a stable price until such a time as they fully monetise one or all of the platforms.

I think this is incredibly positive news. The fact that they are quadrupling the dose really does back up that its safe with no side effects.

Selecting a candidate to take forward (SCOV2) suggests they are seeing better immune responses from this version (which was to be expected)

Giving single dose to people who have already had covid looks like they are trying to make it as pallitable as possible to the UK booster market. I suspect that most people who have already had booster jabs and been infected would probably think they don't need any more jabs. If we can prove big benefit from just a single "jab" then could get more people willing.

This does seem like they are building a good portfolio of evidence for a larger UK booster trial. I also wonder if the UK government would step in and fund the trial/pre purchase boosters.

The only frustrating part for me is that Scancell are not making more of this in the press. Why are we only finding out about this in detail from the trial registry??

exactly Burble. This patent alone could be worth hundreds of millions, if not billions, in the event that the Moditope platform gets sold near term.

Because the underlying IP is what generates the value in the company in the event of a buyout. The "focus" may be on Modi 1 in the clinic, but if the concept proves successful, then the "land grab" of an entirely new treatment method is controlled by Scancell as a consequence of the ongoing work to identify and patent the SIPTMs.

I am genuinely staggered that you could think this not important to a biotech.

Hi Bermuda - have you had chance to review the patent? Is this a new SIPTM? Modi-3 or 4?

@Bermudashorts - correct we were told that the protocol had changed back in March, yet those changes have not been reflected in the trial registry (which is surprising to me - does responsibility for this reside with the lead clinician?)

Given that we are not seeing those RNS'd protocol changes, i think it is reasonable to consider that there may have been other changes. Picking up on the observation that the recruitment poster now says you will be given "one or two" injections, the original trial was designed to test both SCOV1 and SCOV2 to see which elicited the best response and at what dose. Making an assumption, but if there were further un-announced protocol changes to expand out enough to be considered a phase 2, it might be reasonable to assume that they had selected between SCOV1 and 2 as to which candidate to take forward and at what doses, hence the fewer injections.

@Douve87 - Has there been delays with the covid trial? Judging from the other thread it seems like we have an adjusted protocol - something that could and should be RNS'd or at least updated on the Trials Registry in South Africa (but wasn't last time i checked).

Unless you are maybe misreading this part - "There has still been covid issues with the trials but they are getting better. Movment soon". I read that as challenges with starting the cancer trials due to covid, rather than issues with the covid trial. Again, clarification that could be resolved with an official statement rather than hearsay.

Finally - I have long felt that the company should be doing periodic statements to shareholders to update on progress. Even if the update is that no trial progress has been made. It shouldn't always be driven by mandatory release of news dictated by the minimum required by law.

would be even more great news if the company actually released it to the public officially.

It specifically states AIM follow on offering... so this surely means the historic fund raising through shares.

I imagine it would be considered highly unethical to tell potential patients that the trial was open to recruitment when it wasn't.

Also they have formally told the markets that the trial is recruiting - I expect it would be against some law to make false statements to the market.

i stand by my theory that Intensive Care capacity will be a big factor in the trial sites coming live. The Liverpool site may be keen and have patients ready, but until Liverpool University Hospital Trust (or whichever hospital is nearest) agrees to preserve an ITU bed then I doubt patient enrolment or dosing can start.

Edinburgh (which is recruiting) has significantly increased their ITU capacity in response to covid and currently has low number of covid patients in ITU across Scotland.

The moditope trial is really 4 trials in 1 - so i wonder if the company would consider FPD only when a patient from each cohort has been dosed. It's possible I suppose.

they RNS'd that they are recruiting, which means exactly that. If they were waiting for the other sites, then they wouldn't be recruiting. Not being facetious - I just think it is as simple as that.

If modi 1 delivers in humans what it has done preclinical, then there will be a bidding war for the platform - imho. It has that much potential.

...and I've just seen Bobbust post from earlier saying the same thing.

Well they do say great minds think alike.